Management of polycystic ovary syndrome

Women's Health

Volumn 3, Issue 3, 2007, Pages 335-367

  Yasmin, Ephia ^a   Balen, Adam H ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Insulin resistance; Insulin sensitizers; Ovulation induction; Polycystic ovary syndrome; Weight loss

Indexed keywords

ANTIANDROGEN; AROMATASE INHIBITOR; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; CYPROTERONE ACETATE; DIANE; DIAZOXIDE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; ESTROGEN; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GESTAGEN; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PHENFORMIN; PIOGLITAZONE; PROGESTERONE; ROSIGLITAZONE; SIBUTRAMINE; SPIRONOLACTONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNINDEXED DRUG;

ABNORMAL FECES; ADJUVANT THERAPY; ANEMIA; ANOVULATION; CALORIC RESTRICTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DEFECATION DISORDER; DEFECATION URGENCY; DIATHERMY; DIET THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYSIS; FATIGUE; FERTILIZATION IN VITRO; HAIR LOSS; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; INFERTILITY; INSULIN SENSITIVITY; INTRAUTERINE INSEMINATION; LACTIC ACIDOSIS; LIBIDO DISORDER; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW CALORY DIET; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MENSTRUAL IRREGULARITY; META ANALYSIS; MONOTHERAPY; MOOD CHANGE; MUSCLE CRAMP; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SYSTEMATIC REVIEW; TERATOGENICITY; THERAPY RESISTANCE; THROMBOEMBOLISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 34248637944     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.3.3.335     Document Type: Review

References (133)

1. Balen A: Pathogenesis of polycystic ovary syndrome - the enigma unravels? Lancet 354(9183), 966-967 (1999).
2. Franks S: Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J. Clin. Endocrinol. Metab. 91(3), 786-789 (2006).
3. Azziz R, Carmina E, Dewailly D et al.: Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91(11), 4237-4245 (2006).
4. Franks S: Polycystic ovary syndrome: a changing perspective. Clin. Endocrinol. (Oxf) 31(1), 87-120 (1989).
5. Balen AH, Conway GS, Kaltsas G et al.: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum. Reprod. 10(8), 2107-2111 (1995).
6. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1), 41-47 (2004).
7. Balen AH, Conway GS, Homburg R, Legro RS: Polycystic Ovary Syndrome: A Guide to Clinical Management, Taylor & Francis Group, London, UK, 203 (2005).
8. Norman RJ, Davies MJ, Lord J, Moran LJ: The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol. Metab. 13(6), 251-257 (2002).
9. Kiddy DS, Hamilton-Fairley D, Bush A et al.: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 36(1), 105-111 (1992).
10. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88(2), 812-819 (2003).
11. Lord JM. Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327(7421), 951-953 (2003).
12. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH: Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum. Reprod. 21(1), 80-89 (2006).
13. Pasquali R, Gambined A, Pagotto U: The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 113(10), 1148-1159 (2006).
14. Segal KR, Dunaif A: Resting metabolic rate and postprandial thermogenesis in polycystic ovarian syndrome. Int. J. Obes. 14(7), 559-567 (1990).
15. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS: A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil. Steril. 81(3), 630-637 (2004).
16. Holte J. Bergh T, Berne C, Wide L, Litheu H: Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80(9), 2586-2593 (1995).
17. Huber-Buchholz MM, Carey DG, Norman RJ: Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab. 84(4), 1470-1474 (1999).
18. Hu FB, Manson JE, Stampfer MJ et al.: Diet, lifestyle, and the risk of Type 2 diabetes mellitus in women. N. Engl. J. Med. 345(11), 790-797 (2000).
19. Anderson JW, Vichitbandra S, Qian W, Kryscio RJ: Long-term weight maintenance after an intensive weight-loss program. J. Am. Coll. Nutr. 18(6), 620-677 (1999).
20. Jakicic JM, Marcus BH, Gallagher KI, Napolitano M, Lang W. Effect of exercise duration and intensity on weight loss in overweight. sedentary women: a randomized trial. JAMA 290(10), 1323-1330 (2003).
21. Diamanti-Kandarakis E, Piperi C, Alexandraki K et al.: Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 55(4), 494-500 (2006).
22. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL: Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 90(2), 729-733 (2005).
23. Sibutramine Adolescent Study Group: Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann. Intern. Med. 145(2), 81-90 (2006).
24. Elliott WJ: Drug interactions and drugs that affect blood pressure. J. Clin. Hypertens. (Greenwich) 8(10), 731-737 (2006).
25. Wiegratz I, Kutschera E, Lee JH et al.: Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 67(1), 25-32 (2003).
26. Diamanti-Kandarakis E, Baillargeon JP. Iuorno MJ, Jakubowicz DJ, Nestler JE: A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J. Clin. Endocrinol. Metab. 88(5), 1927-1932 (2003).
27. Futterweit W: Polycystic ovary syndrome: clinical perspectives and management. Obstet. Gynecol. Surv. 54(6), 403-413 (1999).
28. Godsland IF, Crook D, Wynn V: Clinical and metabolic considerations of long-term oral contraceptive use. Am. J. Obstet. Gynecol. 166(6 Pt 2), 1955-1963 (1992).
29. Peterson LS, Oakley D, Potter LS, Darroch JE: Women's efforts to prevent pregnancy: consistency of oral contraceptive use. Fam. Plann, Perspect. 30(1), 19-23 (1998).
30. Spellacy WN, Tsibris AM, Tsibris JC, George S, Chez RA, O'Brien WF: Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinyl estradiol. Contraception 49(2), 125-130 (1994).
31. Cibula D, Sindelka G, Hill M, Fanta M, Skrha J, Zlvny J: Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum. Reprod. 17(1), 76-82 (2002).
32. Falsetti L, Gambera A, Tist G: Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum. Reprod. 16(1), 36-42 (2001).
33. Palep-Singh M, Mook K, Barth J, Balen A: An observational study of Yasmin in the management of women with polycystic ovary syndrome. J. Fam. Plann. Riprod. Health Care 30(3), 163-165 (2004).
34. Batukan C, Muderris II: Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil. Steril. 85(2), 436-440 (2006).
35. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R: The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 69(4 Suppl.), 2-15 (2002).
36. Farquhar C, Lee O, Toomath R, Jepson R: Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst. Rev. 4, CD000194 (2001).
37. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G: Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur. J. Endocrinol. 141(4), 361-367 (1999).
38. Tartagni M, Schonauer MM, Cicinelli E et al.: Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertil. Steril. 82(3), 752-755 (2004).
39. Bayram F, Muderris I, Guven M, Ozcelik B, Kelestimur F: Low-dose (2.5 mg/ day) finasteride treatment in hirsutism. Gynecol. Endocrinol. 17(5), 419-422 (2003).
40. Pucci E, Genazzani AD, Monzani F et al.: Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol. Endocrinol. 9(3), 221-228 (1995).
41. Paoletti AM, Cagnacci A, Orru M, Ajossa S, Guerriero S, Melis GB: Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Fertil. Steril. 72(3), 448-453 (1999).
42. Ibanez L, Potau N, Marcos MV, de Zegher F: Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism, in nonobese, adolescent girls: effect of flutamide. J. Clin. Endocrinol. Metab. 85(9), 3251-3255 (2000).
43. Eagleson CA, Gingrich MB, Pastor CL et al.: Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab. 85(11), 4047-4052 (2000).
44. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante GJ: Hormonal effects of flutamide in young women with polycystic ovary syndrome. Clin. Endocrinol. Metab. 83(1), 99-102 (1998).
45. Inaba M, Anthony J, McKinstry CJ: Histologic study of the regeneration of axillary hair after removal with subcutaneous tissue shaver. Invest. Dermatol. 72(5), 224-231 (1979).
46. Richards RN, Uy M, Meharg G: Temporary hair removal in patients with hirsutism: a clinical study. Cutis 45(3), 199-262 (1990).
47. Dierickx C, Alora MB, Dover JS: A clinical overview of hair removal using lasers and light sources. Dermatol. Clin. 17(2), 357-366 (1999).
48. Balfour JA, McClellan K: Topical eflornithine. Am. J. Clin. Dermatol. 2(3), 197-201 (2001).
49. Malhotra B, Noveck R, Behr D, Palmisano M: Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair. J. Clin. Pharmacol. 41(9), 972-978 (2001).
50. Nestler JE, Barlascini CO, Matt DW et al.: Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 68(6), 1027-1032 (1989).
51. Williams RH, Palmer JP: Farewell to phenformin for treating diabetes mellitus. Ann. Intern. Med. 83(4), 567-568 (1975).
52. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF: Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. 12(2), 235-246 (1981).
53. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J: Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb. Haemost. 57(3), 326-328 (1987).
54. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333(9), 550-554 (1995).
55. Cusi K, Consoli A, DeFronzo, RA: Metabolic effects of metformin on glucose and lactate metabolism in noninsutin-dependent diabetes mellitus. J. Clin. Endocrinal. Metab. 81(11), 4059-4067 (1996).
56. Bailey CJ: Metformin - an update. Gen. Pharmacol. 24(6), 1299-1309 (1993).
57. Prager R, Schernthaner G, Graf H: Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabet. Metab. 12(6), 346-350 (1986).
58. Widen EI, Eriksson JG, Groop, LC: Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 41(3), 354-358 (1992).
59. Sarabia V, Lam L, Burdett E, Leiter LA, Klip A: Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J. Clin. Invest. 90(4), 1386-1395 (1992).
60. Rudnichi A, Fontbonne A, Salar M: The effect of metformin on the metabolic anomalies associated with android type body fat distribution. Results of the BIGPRO trial. Diabetes 43, 150-156 (1994).
61. Stith BJ, Woronoff K, Wiernsperger N: Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin. Biochem. Pharmacol. 55(4), 533-536 (1998).
62. Essah PA, Apridonidze T, Iuorno MJ, Nestler JE: Effects of short-term and longterm metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. Fertil. Steril. 86(1), 230-232 (2006).
63. Diamanti-Kandarakis E, Kouli C, Tslanateli T, Bergiele A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. J. Endocrinol. 138(3), 269-274 (1998).
64. Glueck CJ, Streicher P, Wang P: Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin. Pharmacother. 3(8), 1177-1189 (2002).
65. Baillargeon JP, Iuorno MJ, Nestler JE: Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol. 46(2), 325-340 (2003).
66. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17 α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med. 335(9), 617-623 (1996).
67. De Leo V, la Marca A, Petraglia F: Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr. Rev. 24(5), 633-667 (2003).
68. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenarrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J. Clin. Endocrinol. Metab. 85(10), 3526-3530 (2000).
69. Acbay O, Gundogdu S: Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil. Steril. 65(5), 946-949 (1996).
70. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82(2), 524-530 (1997).
71. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327(7421), 951-953 (2003).
72. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81(9), 3299-3306 (1996).
73. Ehrmann DA, Schneider DJ, Sobel BE et al.: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82(7), 2108-2116 (1997).
74. Henry RR: Thiazolidinediones. Endocrinol. Metab. Clin. North Am. 26(3), 553-573 (1997).
75. Tolman KG, Chandramouli J: Hepatotoxicity of the thiazolidinediones. Clin. Liver Dis. 7(2), 369-379 (2003).
76. Romualdi D, Guido M, Ciampelli M et al.: Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum. Reprod. 18(6), 1210-1218 (2003).
77. Sepilian V, Nagamani M: Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J. Clin. Endocrinol. Metab. 90(1), 60-65 (2005).
78. Ortega-Gonzalez C. Luna S, Hernandez L et al.: Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90(3), 1360-1365 (2005).
79. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan GN: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N. Engl. J. Med. 340(17), 1314-1320 (1999).
80. Iuorno MJ, Jakubowicz DJ, Baillargeon JP et al.: Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr. Pract. 8(6), 417-423 (2002).
81. Gerli S, Mignosa M, Di Renzo, GC: Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur. Rev. Med. Pharmacol. Sci. 7(6), 151-159 (2003).
82. Adams J, Polson DW, Franks S: Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J. (Clin. Res. Ed.) 293(6543), 355-359 (1986).
83. Hull MG: Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol. Endocrinol. 1(3), 235-245 (1987).
84. Adashi EY: Clomiphene citrate: mechanism(s) and site(s) of action - a hypothesis revisited. Fertil. Steril. 42(3), 331-344 (1984).
85. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC: A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil. Steril. 77(1), 91-97 (2002).
86. Macgregor AH, Johnson JE, Bunde CA: Further clinical experience with clomiphene citrate. Fertil. Steril. 19(4), 616-622 (1968).
87. Garcia J, Jones GS, Wentz AC: The use of clomiphene citrate. Fertil. Steril. 28(7), 707-717 (1977).
88. Dickey RP, Holtkamp DE: Development, pharmacology and clinical experience with clomiphene citrate. Hum. Reprod. Update 2(6), 483-506 (1996).
89. Dickey RP, Taylor SN, Curole DN, Rye PH, Pyrzak R: Incidence of spontaneous abortion in clomiphene pregnancies. Hum. Reprod. 11(12), 2623-2628 (1996).
90. Franks S, Gilling-Smith C: Advances in induction of ovulation. Curr. Opin. Obstet. Gynecol. 6(2), 136-140 (1994).
91. Kousta E, White DM, Franks S: Modern use of clomiphene citrate in induction of ovulation. Hum. Reprod. Update 3(4), 359-365 (1997).
92. Brinton LA, Lamb EJ, Moghissi KS et al.: Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet. Gynecol. 103(6), 1194-1203 (2004).
93. Ness RB, Cramer DW, Goodman MT et al.: Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am. J. Epidemiol. 155(3), 217-224 (2002).
94. Rossing MA, Tang MT, Flagg EW et al.: A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am. J. Epidemiol. 160(11), 1070-1078 (2004).
95. Agarwal SK, Buyalos RP: Corpus luteum function and pregnancy rates with clomiphene citrate therapy: comparison of human chorionic gonadotrophin-induced versus spontaneous ovulation. Hum. Reprod. 10(2), 328-331 (1995).
96. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F: Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332(7556), 1485 (2006).
97. Legro RS, Barnhart HX, Schlaff WD et al.: Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356(6), 551-566 (2007).
98. Homburg R, Levy T, Ben-Rafael Z: A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil. Steril. 63(4), 729-733 (1995).
99. Hamilton-Fairley D, Franks S: Common problems in induction of ovulation. Clin. Obstet. Gynaecol. 4(3), 609-625 (1990).
100. van Dessel HJ, Schoot BC, Schipper I, Dahl KD, Fauser BC: Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen. Hum. Reprod. 11(3), 478-485 (1996).
101. Hugues JN, Cedrin-Durnerin I, Howles CM; FSH OI Study Group: The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study. Hum. Reprod. 21(11), 2817-2822 (2006).
102. Farhl J, Jacobs HS: Early prediction of ovarian multifollicular response during ovulation induction in patients with polycystic ovary syndrome. Fertil. Steril. 67(3), 459-462 (1997).
103. Bayram M, van Wely M, van der Veen F: Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst. Rev. (4), CD000412 (2006).
104. Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P: Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst. Rev (3), CD001122 (2005).
105. Amer SA, Li TC, Ledger WL: Ovulation induction using laparoscopic ovarian drilling in women with polycystic ovarian syndrome: predictors of success. Hum. Reprod. 19(8), 1719-1724 (2004).
106. Gjonnaess H: Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil. Steril. 41(1), 20-25 (1984).
107. Amer SA, Li TC, Cooke ID: Laparoscopic ovarian diathermy in women with polycystic ovarian syndrome: a retrospective study on the influence of the amount of energy used on the outcome. Hum. Reprod. 17(4), 1046-1051 (2002).
108. Balen AH, Jacobs HS: A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome. Fertil. Steril. 62(5), 921-925 (1994).
109. Bayram N, van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F: Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 328(7433), 192 (2004).
110. Mitwally MF, Casper RF: Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil. Steril. 75(2), 305-309 (2001).
111. Biljan MM, Hemmings R, Brassard N: The outcome of 150 babies following treatment with letrozole or letrozole and gonadotropins. (2005) (Abstract ASRM).
112. Tulandi T, Martin J, Al-Fadhli R et al.: Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil. Steril. 85(6), 1761-1765 (2006).
113. Casper RF, Mitwally MF: Review: aromatase inhibitors for ovulation induction. J. Clin. Endocrinol. Metab. 91(3), 760-771 (2006).
114. Homburg R: The management of infertility associated with polycystic ovary syndrome. Reprod. Biol. Endocrinol. 1, 109 (2003).
115. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D: Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet. Gynecol. Scand. 84(7), 611-616 (2005).
116. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC: A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum. Reprod. Update 12(1), 13-21 (2006).
117. Tang T, Gianville J, Orsi N, Barth JH, Balen AH: The use of metformin for women with PCOS undergoing IVF treatment. Hum. Reprod. 21(6), 1416-1425 (2006).
118. Mikkelsen AL: Strategies in human in-vitro maturation and their clinical outcome. Reprod. Biomed. Online 10(5), 593-599 (2005).
119. Cha KY, Chung HM, Lee DR et al.: Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil. Steril. 83(5), 1461-1465 (2005).
120. Hillard PJ: Oral contraceptives and the management of hyperandrogenism - polycystic ovary syndrome in adolescents. Endocrinol. Metab. Clin. North Am. 34(3), 707-723 (2005).
121. Zapanti E, Kiapekou E, Loutradis D: Treatment options of polycystic ovary syndrome in adolescence. Pediatr. Endocrinol. Rev. 3(Suppl. 1), 208-213 (2006).
122. Glueck CJ, Aregawi D, Winiarska M et al.: Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. 19(6), 831-842 (2006).
123. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A: Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab. 90(6). 3236-3242 (2005).
124. Rajkhowa M, Glass MR, Rutherford AJ, Michelmore K, Balen AH: Polycystic ovary syndrome: a risk factor for cardiovascular disease? BJOG 107(1), 11-18 (2000).
125. Balen A, Rajkowha M: Polycystic ovary syndrome - a systemic disorder? Best Pract. Res. Clin. Obstet. Gynaecol. 17(2), 263-274 (2003).
126. Cussons AJ, Stuckey BG, Watts GF: Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 185(2), 227-239 (2006).
127. Wild RA: Long-term health consequences of PCOS. Hum. Reprod. Update 8(3), 231-241 (2002).
128. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS: Mortality of women with polycystic ovary syndrome at long-term follow-up. J. Clin. Epidemiol. 51(7), 581-586 (1998).
129. Giudice LC: Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract. Res. Clin. Endocrinol. Metab. 20(2), 235-244 (2006).
130. Coffey S, Bano G, Mason HD: Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36). Gynecol. Endocrinol. 22(2), 80-86 (2006).
131. Hahn S, Janssen OE, Tan S et al.: Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur. J. Endocrinol. 153(6), 853-860 (2005).
132. Amato P, Simpson JL: The genetics of polycystic ovary syndrome. Best Pract. Res. Clin. Obstet. Gynaecol. 18(5), 707-718 (2004).
133. Franks S: Candidate genes in women with polycystic ovary syndrome. Fertil. Steril. 86(Suppl.), S15 (2006).